HIV and Bone Complications: Understudied Populations and New Management Strategies

Overview

Journal Curr HIV/AIDS Rep

Publisher Current Science

Specialty Infectious Diseases

Date 2016 Oct 13

PMID 27730445

Citations 18

Authors

Michael T Yin

Todd T Brown

Affiliations

Soon will be listed here.

Abstract

The higher risk of osteoporosis and fracture associated with HIV infection and certain antiretrovirals has been well established and the need for risk stratification among older adults increasingly recognized. This review focuses upon emerging data on bone complications with HIV/HCV coinfection, in children and adolescents, and with pre-exposure prophylaxis (PrEP), as well as new management strategies to minimize the negative effects of ART on bone.

Citing Articles

Epigenetic Aging and Musculoskeletal Outcomes in a Cohort of Women Living With HIV.

Shiau S, Zumpano F, Wang Z, Shah J, Tien P, Ross R J Infect Dis. 2024; 229(6):1803-1811.

PMID: 38366369 PMC: 11175700. DOI: 10.1093/infdis/jiae016.

Bone Mineral Density and Trabecular Bone Score Changes throughout Menopause in Women with HIV.

Milic J, Renzetti S, Morini D, Motta F, Carli F, Menozzi M Viruses. 2023; 15(12).

PMID: 38140615 PMC: 10747369. DOI: 10.3390/v15122375.

Evaluation of bone mineral density, microarchitecture, and detection of fractures on young patients living with human immunodeficiency virus: when and how to screen?.

Gehrke B, Farias M, Wildemberg L, Ferraiuoli G, Ribeiro V, Bosgnoli R Endocrine. 2023; 83(1):214-226.

PMID: 37673836 DOI: 10.1007/s12020-023-03501-9.

Geriatric conditions and healthcare utilisation in older adults living with HIV.

Greene M, Shi Y, Boscardin J, Sudore R, Gandhi M, Covinsky K Age Ageing. 2022; 51(5).

PMID: 35511728 PMC: 9271234. DOI: 10.1093/ageing/afac093.

Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis.

Pornpaisalsakul K, Songtaweesin W, Tepmongkol S, Wongharn P, Kawichai S, Suponsilchai V J Int AIDS Soc. 2020; 23(10):e25624.

PMID: 33040465 PMC: 7548100. DOI: 10.1002/jia2.25624.

References

Vigano A, Mora S, Giacomet V, Stucchi S, Manfredini V, Gabiano C . In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers. Antivir Ther. 2011; 16(8):1259-66. DOI: 10.3851/IMP1909. View

Mirembe B, Kelly C, Mgodi N, Greenspan S, Dai J, Mayo A . Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis. J Acquir Immune Defic Syndr. 2016; 71(3):287-94. PMC: 4755358. DOI: 10.1097/QAI.0000000000000858. View

Gallant J, Brunetta J, Crofoot G, Benson P, Mills A, Brinson C . Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. J Acquir Immune Defic Syndr. 2016; 73(3):294-298. PMC: 5172523. DOI: 10.1097/QAI.0000000000001069. View

Rockstroh J, Mocroft A, Soriano V, Tural C, Losso M, Horban A . Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 2005; 192(6):992-1002. DOI: 10.1086/432762. View

Zemel B, Leonard M, Kelly A, Lappe J, Gilsanz V, Oberfield S . Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children. J Clin Endocrinol Metab. 2010; 95(3):1265-73. PMC: 2841534. DOI: 10.1210/jc.2009-2057. View

Hoy J, Young B . Do people with HIV infection have a higher risk of fracture compared with those without HIV infection?. Curr Opin HIV AIDS. 2016; 11(3):301-5. DOI: 10.1097/COH.0000000000000249. View

Mills A, Arribas J, Andrade-Villanueva J, DiPerri G, van Lunzen J, Koenig E . Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2015; 16(1):43-52. DOI: 10.1016/S1473-3099(15)00348-5. View

Jacobson D, Lindsey J, Gordon C, Moye J, Hardin D, Mulligan K . Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. AIDS. 2010; 24(5):687-96. PMC: 3154736. DOI: 10.1097/QAD.0b013e328336095d. View

Zuccotti G, Vigano A, Gabiano C, Giacomet V, Mignone F, Stucchi S . Antiretroviral therapy and bone mineral measurements in HIV-infected youths. Bone. 2010; 46(6):1633-8. DOI: 10.1016/j.bone.2010.02.029. View

10.

Brown T, Moser C, Currier J, Ribaudo H, Rothenberg J, Kelesidis T . Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. J Infect Dis. 2015; 212(8):1241-9. PMC: 4577040. DOI: 10.1093/infdis/jiv194. View

11.

Bernardino J, Mocroft A, Mallon P, Wallet C, Gerstoft J, Russell C . Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV. 2015; 2(11):e464-73. DOI: 10.1016/S2352-3018(15)00181-2. View

12.

Kovacs A, Al-Harthi L, Christensen S, Mack W, Cohen M, Landay A . CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis. 2008; 197(10):1402-7. PMC: 2443164. DOI: 10.1086/587696. View

13.

Redondo-Cerezo E, Casado-Caballero F, Martin-Rodriguez J, Hernandez-Quero J, Escobar-Jimenez F, Gonzalez-Calvin J . Bone mineral density and bone turnover in non-cirrhotic patients with chronic hepatitis C and sustained virological response to antiviral therapy with peginterferon-alfa and ribavirin. Osteoporos Int. 2014; 25(6):1709-15. DOI: 10.1007/s00198-014-2663-z. View

14.

Hileman C, Eckard A, McComsey G . Bone loss in HIV: a contemporary review. Curr Opin Endocrinol Diabetes Obes. 2015; 22(6):446-51. PMC: 4663974. DOI: 10.1097/MED.0000000000000200. View

15.

Brown T, Mallon P . Editorial: Working towards an understanding of bone disease in HIV. Curr Opin HIV AIDS. 2016; 11(3):251-2. DOI: 10.1097/COH.0000000000000277. View

16.

Curran A, Martinez E, Saumoy M, Del Rio L, Crespo M, Larrousse M . Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS. 2011; 26(4):475-81. DOI: 10.1097/QAD.0b013e32834f3507. View

17.

Aurpibul L, Cressey T, Sricharoenchai S, Wittawatmongkol O, Sirisanthana V, Phongsamart W . Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing. Pediatr Infect Dis J. 2015; 34(4):392-7. DOI: 10.1097/INF.0000000000000633. View

18.

Huang J, Meixner L, Fernandez S, McCutchan J . A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS. 2008; 23(1):51-7. PMC: 3477869. DOI: 10.1097/QAD.0b013e32831c8adc. View

19.

Landovitz R . Preexposure Prophylaxis For HIV Prevention: What We Know and What We Still Need to Know for Implementation. Top Antivir Med. 2015; 23(2):85-90. PMC: 6148938. View

20.

Kovacs A, Karim R, Mack W, Xu J, Chen Z, Operskalski E . Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis. 2010; 201(6):823-34. PMC: 3105602. DOI: 10.1086/650997. View